Gerodermia osteodysplastica is a hereditary segmental progeroid disorder affecting skin, connective tissues, and bone that is caused by loss-of-function mutations in GORAB. The golgin, RAB6-interacting (GORAB) protein localizes to the Golgi apparatus and interacts with the small GTPase RAB6. In this study, we used different approaches to shed more light on the recruitment of GORAB to this compartment. We show that GORAB best colocalizes with trans-Golgi markers and is rapidly displaced upon Brefeldin A exposition, indicating a loose association with Golgi membranes. A yeast two-hybrid screening revealed a specific interaction with the small GTPase ADP-ribosylation factor (ARF5) in its active, GTP-bound form. ARF5 and RAB6 bind to GORAB via the same internal Golgi-targeting RAB6 and ARF5 binding (IGRAB) domain. Two GORAB missense mutations identified in gerodermia osteodysplastica patients fall within this IGRAB domain. GORAB carrying the mutation p. Ala220Pro had a cytoplasmic distribution and failed to interact with both RAB6 and ARF5. In contrast, the p. Ser175Phe mutation displaced GORAB from the Golgi compartment to vesicular structures and selectively impaired ARF5 binding. Our findings indicate that the IGRAB domain is crucial for the Golgi localization of GORAB and that loss of this localization impairs its physiological function.
INTRODUCTION
Loss-of-function mutations in golgin, Ras-related in brain 6 (RAB6)-interacting (GORAB; also named SCYL1-binding protein 1 or NTKL-binding protein 1) cause the autosomal recessively inherited disease gerodermia osteodysplastica (GO, OMIM 231070; Hennies et al., 2008) . Patients suffer from lax, wrinkly skin with abnormal dermal elastic fibers, malar hypoplasia, and osteoporosis leading to increased bone fragility. As these clinical features are reminiscent of changes observed during human aging, GO is regarded as a segmental progeroid disorder (Martin and Oshima, 2000) . GORAB is predicted to have two coiled-coil domains, and it resides in the Golgi compartment, where it interacts with the guanosine triphosphate (GTP)-bound form of the small Ras-like GTPase RAB6 (Hennies et al., 2008) , suggesting that it belongs to the family of golgin proteins that have different roles in Golgi-related transport processes. In addition, a cytosolic and nuclear localization of GORAB and an interaction with the proteins SCYL1, MDM2, and PIRH2 have been described (Di et al., 2003; Zhang et al., 2005; Yan et al., 2010) . However, the exact physiological function of GORAB that is disturbed in GO remains largely unknown.
The Golgi apparatus is the central hub of intracellular membrane trafficking. In mammalian cells, it is a membranous organelle composed of stacked cisternae linked into ribbons (Palade, 1975) . After their synthesis, new proteins destined for the plasma membrane or for secretion pass through this compartment and are post-translationally modified, sorted, and transported by membranous carriers that bud from the Golgi membranes (Dunphy et al., 1981; Rothman et al., 1982) . Important players in Golgi function and transport are the small Ras-like GTPases of the RAB, ADPribosylation factor (ARF), and ADP-ribosylation factor-like families. They are molecular switches, which are membrane associated when in their active, GTP-bound conformation. When activated, they recruit effector proteins that modify membrane lipids, assist in cargo recruitment, guide vesicle budding, vesicle tethering, and fusion. Hence, small GTPases help to give a unique identity to the membrane of the subcompartment they localize to (Pfeffer, 2001; Zerial and McBride, 2001; Gillingham and Munro, 2007; Barr, 2013) . The golgins are a heterogeneous group of proteins localized at the Golgi apparatus interacting with small GTPases of the RAB, ARF, and ADP-ribosylation factor-like families (Barr and Short, 2003) . Golgins extend from the cytosolic face of Golgi membranes as rod-like structures with coiled-coils and are involved in vesicle trafficking, but they are also essential for Golgi integrity and homeostasis (Behnia and Munro, 2005; Short et al., 2005) . The GORAB interaction partner RAB6 is known to be involved in several important events of retrograde trafficking, suggesting that also GORAB might have a related function (Mallard et al., 2002; Short et al., 2002; Starr et al., 2010) .
In this study, we specified the subcellular localization of GORAB and identified the small GTPase ARF5 as a previously unreported binding partner. We furthermore mapped down the region of GORAB responsible for interaction with the two small GTPases RAB6 and ARF5 and for Golgi targeting. We showed that two GORAB missense mutations within this targeting domain found in GO impaired interaction with both GTPases and Golgi localization to different degrees.
RESULTS

GORAB localizes to the trans-Golgi
In cell types relevant for the GO phenotype, a strong Golgi localization of GORAB is evident (Supplementary Figure S1 online). To better understand GORAB's function, we wanted to investigate this subcellular localization in more detail. Nocodazole disassembles the microtubule network and leads to fragmentation of the Golgi apparatus into so-called ministacks (Rogalski and Singer, 1984) , making it easier to discern spatial relation of different Golgi markers. After Nocodazole treatment of HeLa cells and human skin fibroblasts, GORAB showed a clear separation from the cisGolgi marker GM130 (Nakamura et al., 1995; Figure 1a and b) . In contrast, the trans-Golgi network marker TGN46 (Prescott et al., 1997) and GORAB strongly overlapped. The best colocalization was observable for p230 (Gleeson et al., 1996) , indicating that GORAB is localized mainly in the transGolgi. Our previous studies showed that loss of GORAB did not influence the kinetics of Brefeldin A (BFA)-induced Golgi disassembly, but the behavior of GORAB itself in cells treated with BFA has not yet been examined (Fischer et al., 2012) . This drug locks the small GTPase ARF1 in a complex with its guanosine nucleotide exchange factor disrupting endoplasmic reticulum (ER)-Golgi transport (Liang et al., 1997; Sciaky et al., 1997) . After BFA treatment, Golgi matrix proteins such as GM130 are found at distinct ER-exit sites (Golgi haze), whereas more loosely associated proteins such as the Golgi SNARE GS15 are found diffusely in the ER lumen (Lippincott-Schwartz et al., 1989) . As expected, application of BFA instantaneously disrupted the formation of the coat protein complex 1 (COPI) coatomer (Klausner et al., 1992) within 5 minutes (Figure 1c) . GM130 stayed at the Golgi and became redistributed to ER-exit sites after 15 minutes ( Figure 1c ). The Golgi SNARE GS15 and GORAB showed a reduced Golgi signal after 5 minutes of BFA treatment and a complete redistribution to the ER after 15 minutes. These results indicate that, unlike a Golgi matrix protein, GORAB seems only loosely associated with membranes of the transGolgi network.
RAB6 interacts with the central amino acids 99 to 277 of GORAB
In our initial studies, we showed that GORAB interacts specifically with the constitutively active form of RAB6 (RAB6 p.Gln72Ala) but not the GDP-locked inactive form (RAB6 p.Thr27Asn) and that GORAB colocalizes with RAB6 at the Golgi apparatus (Hennies et al., 2008) . Here we wanted to further map the interaction domain of RAB6 on GORAB. First, we specified the protein sequence of human GORAB, which, in contrast to all other species except primates, possesses two possible start methionines giving rise to proteins with a length of 369 amino acids (aas) or 394 aas, respectively. As a mutation of the downstream methionine codon found in GO leads to a complete loss of GORAB expression, it is likely that this second methionine is the main translation start (Hennies et al., 2008) . To further prove this, we analyzed immunoprecipitated endogenous GORAB from HeLa cells by mass spectrometry. 11 unique peptides for GORAB were identified, among them an N-terminally acetylated peptide starting with the alanine following the second start methionine (Supplementary Figure S2a; Figure S2b online ). As these data corroborate that the 369 aa variant is functionally most relevant, all cDNA and aa positions mentioned in this study refer to this protein.
For yeast 2-hybrid (Y2H) interaction, we used three different fragments dividing GORAB into the N-terminal aas 1 to 277, C-terminal aas 278 to 369, and the central aas 99 to 277 as prey (Figure 2a ). Only yeast transformed with the active form of RAB6 and the N-terminal aas 1 to 277 or the central aas 99 to 277 of GORAB showed growth on selective medium (Figure 2b ). Furthermore, we performed in vitro pulldown assays using GTP-loaded wild-type RAB6 and the GDP-locked RAB6 mutant (p.Thr27Asn) as baits and FLAGtagged GORAB fragments overexpressed in HeLa cells as prey. In contrast to full-length GORAB, neither the N terminus nor the C terminus of GORAB were able to interact with any form of RAB6 (Figure 2c,d , and f). The protein fragment containing aas 99 to 277, however, interacted specifically with wild-type GTP-bound RAB6, but not with inactive RAB6 p.Thr27Asn (Figure 2e ). interaction study with all 19 known human ARF and ADPribosylation factor-like family members (Figure 3a and not shown). ARF5, one of the two class II ADP-ribosylation factors (Volpicelli-Daley et al., 2005) , was the only candidate showing growth. This result was verified by in vitro pulldown assays using glutathione S-transferase-tagged ARF5 p.Gln71Leu (GTP-locked), ARF5 loaded with GDP, and GTP-locked ARF4 p.Gln71Leu in order to prove specificity ( Figure 3b ). When incubated with HeLa lysates, only active ARF5 precipitated endogenous GORAB. Costaining of endogenous GORAB and overexpressed green fluorescent protein-tagged ARF5 p.Gln71Leu in HeLa cells confirmed colocalization of GORAB and ARF5 at the Golgi apparatus ( Figure 3c ).
We performed a Y2H experiment using the different GORAB fragments mentioned above as prey constructs and wild-type ARF5 as bait (Figure 3d ). Only yeast transformed with ARF5 and GORAB 99-277 or GORAB 1-277 constructs grew, implying that aas 99 to 277 suffice for interaction. For verification of this result, we performed in vitro pulldown assays showing that ARF5 p.Gln71Leu and wild-type ARF5 loaded with GTP interacted with FLAG-tagged GORAB, whereas ARF5 loaded with GDP did not (Figure 3e ). For the in vitro mapping, we used GTP-and GDP-loaded wild-type ARF5 protein and incubated them with lysates from HeLa cells transfected with different GORAB fragments. ARF5 was only able to bind to aas 99 to 277, but not to the N or C terminus (Figure 3f -h), indicating that the two small GTPases RAB6 and ARF5 both bind in the region containing aas 99 to 277. We termed this highly conserved region (Supplementary As both small GTPases that we identified as interaction partners for GORAB localize at the Golgi apparatus and bind to the same IGRAB domain, we assumed that Golgi targeting is mediated by this part of the protein. To prove this, we analyzed the subcellular localization of the different GORAB fragments. It should be noted that overexpression of fulllength GORAB frequently leads to the formation of fibrous structures that are not coincident with the Golgi apparatus in a dose-dependent manner (Supplementary Figure S4a was costained with COPI component δCOP, Golgi matrix protein GM130, and Golgi SNARE GS15 (all in red), respectively, by immunofluorescence to monitor the response to the treatment. Scale bars = 10 μm.
Missense mutations in the IGRAB domain disturb ARF5 and RAB6 binding and Golgi targeting
Previously, a p.Ala220Pro missense mutation affecting a highly conserved residue within the minimal (aa 200-277) targeting region of the IGRAB domain (Supplementary Figure S3 online) was described in patients with GO (Al-Dosari and Alkuraya, 2009). In silico analysis of GORAB predicted three coiled-coil regions (aa 130-170, aa 200-250, and aa 270-300) and a reduction of the probability for the aa 200-250 coil from 30% to nearly 0% in GORAB p.Ala220Pro (Supplementary Figure S5a , b online). As no primary cells from a patient carrying the p.Ala220Pro mutation were available, the mutant protein was expressed in HeLa cells. GORAB p.Ala220Pro showed an even distribution throughout the cytoplasm (Figure 5a ). Furthermore, we examined the interaction of the protein variant with the active and inactive forms of RAB6 and ARF5 in in vitro pulldown assays. Cell lysates from GORAB p.Ala220Pro expressing transfected HeLa were used, which showed high expression levels indicating that the protein was stable (Figure 5b and c) . Interestingly, we saw only very weak interaction with both small GTPases (Figure 5b and c), which was corroborated by densitometric quantification (Supplementary Figure S6a  online ). In summary, this GORAB variant is neither able to bind RAB6 nor ARF5 and is not targeted to the Golgi apparatus. The mutation p.Ser175Phe also introduces an exchange of a conserved aa within the IGRAB domain, but outside the minimum Golgi-targeting fragment 200-277 (Gardeitchik et al., 2014) . Depending on the algorithm, the mutation is predicted to reduce the probability for the first coiled-coil below the threshold of 50% (Supplementary Figure S5a (Figure 3b and d) . To prove that loss of ARF5 and RAB6 binding is sufficient to impair GORAB Golgi targeting, we knocked down both proteins by specific siRNAs (Supplementary Figure S7 online) . Loss of both proteins significantly reduced GORAB Golgi staining, albeit the effect was more pronounced for RAB6.
DISCUSSION
In this study, we examined the subcellular localization of GORAB, its dependency on interaction partners, and the effect of GORAB missense mutations on protein interaction and distribution. Although we previously described a Golgi localization of GORAB in primary human fibroblasts and HeLa cells (Hennies et al., 2008) , other studies reported a localization of GORAB in the cytoplasm of SMMC-7721 hepatoma cells (Di et al., 2003) or in the nucleus in neuronal PC12 cells (Liu et al., 2012) , thus implying possible cell typedependent differences. However, in the cell types most likely affected in GO, dermal fibroblasts, and osteoblasts, GORAB has an almost exclusive Golgi localization under normal culturing conditions. In our hands, colocalization studies under different Golgi disrupting conditions implied a localization of GORAB mainly in the trans-Golgi, which has a central role in the terminal modification of N-glycans by the addition of sialic acid and galactose. Interestingly, loss of the trans-Golgi-localized V-type H (c-f) For in vitro pulldown experiments, wild-type, guanosine triphosphate (GTP)-loaded RAB6 (RAB6 GTP) or inactive RAB6 p.Thr27Asn (RAB6 n.act.) were expressed as glutathione S-transferase (GST) fusion proteins and incubated with lysates from HeLa cells transiently transfected with the indicated FLAG-tagged GORAB fragments. The bound protein was analyzed on western blot with a FLAG-specific antibody. CC, coiled-coil. 2012). However, GO patients do not display altered serum protein glycosylation patterns, indicating that GORAB is not crucial for glycosylation processes, at least in hepatocytes (Hennies et al., 2008) . GORAB was initially discovered as an interaction partner of the kinase-like protein SCYL1 (thus GORAB's former names SCYL1BP1 or NTKL-BP1; Di et al., 2003) . However, loss-offunction mutations in murine Scyl1 cause a neuromuscular phenotype not overlapping with GO (Schmidt et al., 2007) , making a close functional relationship between both proteins unlikely. It was shown that SCYL1 is involved in COPI retrograde Golgi-to-ER trafficking and maintenance of Golgi morphology (Burman et al., 2008 (Burman et al., , 2010 . In this study, we identified ARF5 as an additional interaction partner of GORAB by Y2H and pulldown assays. In addition, ARF5 is found on COPI vesicles and might have a role in COPI vesicle coat formation (Popoff et al., 2011) . GORAB does not, however, colocalize with COPI vesicles in HeLa cells under normal conditions, nor is it found in lysates of ARF5-positive COPI vesicles isolated from rat livers (Popoff V., personal communication). It was described that ARF5 is also involved in clathrin-mediated endocytosis of β1 integrin, but not the uptake of transferrin (Moravec et al., 2012; Volpicelli-Daley et al., 2005), suggesting a more ubiquitous distribution of ARF5 throughout the intracellular trafficking pathway. RAB6 is one of the best-studied RAB-GTPases, and it is involved in several intracellular trafficking events, for example, endosome-to-Golgi trafficking (Mallard et al., 2002) . However, the trans-Golgi is also a crucial sorting platform for anterograde transport, and another trans-Golgi RAB6-interacting golgin, PIST (GOP/C), has been shown to influence the transport of several plasma membrane proteins (Cheng et al., 2002; Wente et al., 2005) .
Additional interaction partners of GORAB described in literature are the two ubiquitin ligases, MDM2 and PIRH2 Yan et al., 2010) , that localize to the nucleus or to the nucleus and the cytoplasm, respectively. It cannot be excluded that GORAB might also reach the nucleus in some cell types as described for neuronal PC12 cells (Liu et al., 2012) . A factor that might influence localization and protein-protein interaction is the GORAB N terminus. Western blotting revealed two bands in HeLa and HAF whose size could correspond to the 369 aa and 394 aa forms, respectively. However, no fragments representing the predicted 25 upstream GORAB aas were identified by mass spectrometry, and acetylation of the penultimate alanine residue of the 369 aa form is a typical sign for an aa at the N-terminal end (Helbig et al., 2010) . Similar data can also be found in Proteomics DB. We conclude that in the human cell types that we tested, mainly the short 369 aa form is expressed. The higher bands detected in lysates from COS7, as well as in murine cells (which lack the upstream start methionine), suggest a heavy post-translational modification, which merits further investigation. GORAB was classified as a golgin with predicted coiledcoil elements in the identified RAB6-binding domain (Hennies et al., 2008) . Coiled-coil domains are structural elements found in a variety of proteins with functions ranging from components of the extracellular matrix to transcription factors (Qin et al., 2004) . They are important structural features as they form rigid rods giving the respective parts of the protein an elongated shape. Coiled-coil domains are also known as hubs for protein-protein interaction, mediating, for example, the dimerization of basic leucinezipper transcription factors. Typically, golgins are rather large proteins that are extending from the Golgi membranes, for example, to perform vesicle tethering (Barr and Short, 2003) . For GORAB, two or three coiled-coil domains are predicted to reside between residues 120 and 300. For comparison, in the giantin protein, coiled-coil domains are contained in a stretch of more than 3,000 aas. Thus, for the rather small golgin GORAB to perform a tethering function, the ability to form multimers would be favorable. We showed that high levels of overexpression induce the formation of GORAB-positive fibrous structures reminiscent of fibers formed when intermediate filaments are highly expressed (Singh et al., 2003) . Indeed, the fibers formed by GORAB overexpression also showed staining for vimentin, possibly owing to unspecific aggregation of the coiled-coil domains. We are aware that mislocalization of overexpressed proteins is a problem for biochemical interaction experiments. Therefore, we used endogenous GORAB protein for in vitro pulldown assays whenever possible and made sure that overexpressed FLAGtagged GORAB behaved identically. Colocalization studies were performed as shortly after transfection as possible, and only cells with low expression levels without fibrous artifacts were included. The highly conserved IGRAB domain defined in this study is reminiscent of the GRIP domain of certain trans-golgins (Munro and Nichols, 1999) , although it is not found at the C terminus, but in the protein's center. Although most mutations found in GO entail a loss of the protein, both missense mutants studied here were stable, but altered the binding of the IGRAB domain to RAB6 and ARF5 to different degrees. In GORAB p.Ala220Pro, the exchange of the flexible aa alanine to proline is likely to stiffen the polypeptide backbone, thereby disrupting the IGRAB structure. In GORAB p.Ser175Phe, the exchange of a small for a bulky aa could interfere with the tight packing of the coils. The fact that patients with these mutations showed the typical GO phenotype indicate that the effects must be of comparable severity to the complete protein loss (Al-Dosari and Alkuraya, 2009; Gardeitchik et al., 2014) .
Taken together, we have shown that GORAB is a mainly trans-Golgi-localized protein that interacts with Rab6 and the previously unreported interaction partner ARF5 through its IGRAB domain. Analysis of two missense mutations in the IGRAB domain suggests that loss of proper Golgi targeting of GORAB is a central aspect of the GO pathomechanism.
MATERIALS AND METHODS
Cell culture and drug treatment
HeLa cells were kept in DMEM (Life Technologies, Darmstadt, Germany) supplemented with 5% fetal calf serum (Gibco, Life Technologies, Darmstadt, Germany) and 1% Ultraglutamine (Life Technologies) at 37°C, 5% CO2. Primary skin fibroblasts were cultured in alpha Modified Eagle's Medium (Life Technologies) supplemented with 10% fetal calf serum (Gibco), 1% Ultraglutamine (Invitrogen), and 1% Penicillin/Streptomycin (Life Technologies) at 37°C, 5% CO2. For drug treatment, cells were incubated with normal growth medium supplemented with 5 mg ml − 1 BFA (SigmaAldrich, Munich, Germany) or 33 μM Nocodazole (Sigma-Aldrich) for the indicated time. 
Constructs and plasmids
For transient transfection of mammalian cells, the respective DNAs were amplified from HeLa or skin fibroblast cDNA and cloned into pEGFPC2, pEGFPN3, or pFLAG-CMV-5a (all Life Technologies), respectively, by restriction digestion and ligation. Point mutations were introduced by overlap PCR with primers containing the respective base exchange. Bacterial expression was performed in the pFAT2 (modified pGAT2) vector. Y2H vectors were pFBT9 (modified pGBT9) and pAct2 (Clontech, Takara Bio, Saint-Germain-enLaye, France).
Transient transfection of plasmid DNA
Cells were transfected 24 hours after passage with JetPei (PolyplusTransfection, Illkirch, France) by a modified supplier's protocol. For 15-cm dishes, 940 μl of 0.9% NaCl solution was mixed with 15 μg of DNA and 30 μl of JetPei and added to 10 ml of standard growth medium. For one 6-well plate, 94 μl of 0.9% NaCl solution was mixed with 3 μl of JetPei and 1.5 μg of DNA and added to a volume of 1 ml of standard growth medium. Cells were processed 15-18 hours later.
RNA interference
siRNA oligos against GORAB (5′-ccaugauggucacaacaautt-3′), RAB6 (5′-ucuggugaucaaagaugucuu-3′), and ARF5 (5′-uuacuguccaccaca aagatg-3′) and a negative control siRNA oligo as nontargeting control (Life Technologies) were transfected with INTERFERin (PolyPlus) according to a modified supplier's protocol. Cells were grown for 14 hours at a low density before being transfected. A volume of 90 μl of OptiMEM (Gibco) was mixed with 10 μl of siRNA oligo at a working dilution of 2 μM concentration and 3 μl of INTERFERin, incubated for 10 minutes and then added to 1 ml of fresh standard growth medium for transfection of one well in a six-well plate. Cells were analyzed after 72 hours. Knockdown efficiency was tested by immunofluorescence, western blotting, or quantitative PCR.
Quantitative PCR
We prepared RNA using the Trizol method (Life Technologies). A measure of 1 μg of RNA was reverse-transcribed using the RevertAid kit (Fermentas, Thermo Scientific, Dreieich, Germany). The qPCR was performed with Evagreen (Solis Biodyne, Tartu, Estonia), using specific primers for ARF5, GORAB, RAB6, and GAPDH as endogenous control. Sequences are available on request.
Antibodies
We used a polyclonal rabbit GORAB antibody as described before (Hennies et al., 2008) . Mouse anti-COPI antibody was a kind gift from F.T. Wieland and V. Popoff. The following commercially available antibodies were used: GM130 (BD Biosciences, Heidelberg, Germany), RAB6 (C-19, Santa Cruz Biotechnology, Heidelberg, Germany), giantin (Serotec, Puchheim, Germany), GORAB (SigmaAldrich), GS15 (BD Biosciences), p230 (BD Biosciences), vimentin (Millipore, Schwalbach, Germany), FLAG M2 (Sigma-Aldrich), FLAG (Rabbit; Sigma-Aldrich), and actin (Sigma-Aldrich). Secondary antibodies were Alexa 488-and Alexa 555-labeled (Life Technologies) or HRP-labeled antibodies (Cell Signaling Technology, New England Biolabs, Frankfurt, Germany).
Y2H interaction study
For Y2H experiments, PJ69-4A yeast was transformed with bait and prey plasmids and grown on SC-Leu/-Trp medium plates. Colonies were picked and restreaked on quadruple dropout medium plates (SC-Leu/-Trp/-His/-Ade) and grown for another 2-3 days at 30°C. Growth on selective medium indicates interaction.
Immunofluorescence microscopy
Cells were fixed with 4% paraformaldehyde and permeabilized with 0.1% Saponin in 3% bovine serum albumin/phosphate-buffered saline. Primary antibody incubation was performed overnight Guanosine triphosphate (GTP)-loaded glutathione S-transferase (GST)-RAB6 (RAB6 GTP) or inactive GST-RAB6 p.Thr27Asn (RAB6 n.act.) was used for pulldown of FLAG-tagged GORAB p.Ala220Pro expressed in HeLa cells. Bound (pulldown) and unbound (supernatant) protein fractions were blotted. (c) Same as in b, but wild-type GST-ARF5 was loaded with either GTP (ARF5 GTP) or GDP (ARF5 GDP) and used for pulldown of GORAB p.Ala220Pro. (d) Skin fibroblasts from a patient with the GORAB p.Ser175Phe mutation were stained for GORAB (red) and the Golgi marker GM130 (green). (e) GTP-loaded GST-RAB6 (RAB6 GTP) or inactive GST-RAB6 p.Thr27Asn (RAB6 n.act.) was used to pulldown FLAG-tagged GORAB p.Ser175Phe expressed in HeLa cells. (f) Same as in b, but GTP-locked GST-ARF5 p.Gln71Leu (ARF5 act.) and GST-ARF5, loaded with either GTP (ARF5 GTP) or GDP (ARF5 GDP), were used for the pulldown of GORAB p. Ser175Phe. Scale bars = 10 μm.
at 4°C. Secondary antibodies were applied for 1-2 hours at room temperature. Nuclei were labeled with 4',6-Diamidin-2-phenylindol (Life Technologies). Cells were mounted and imaged with a Zeiss LSM510 Lasermodule and Axiovert 200M system and the Zen2009 software (Zeiss, Oberkochen, Germany).
In vitro pulldown assays
In vitro pulldown assays were performed according to Christoforidis and Zerial, 2000 . In short, bacterially expressed and purified glutathione S-transferase-tagged ARF5 or RAB6 were coupled to Glutathione-S-Sepharose (Thermo Fisher Scientific, Dreieich, Germany), washed with NE100 buffer (20 mM Hepes/NaOH pH 7.5, 100 mM NaCl, 5 mM EDTA, 0.1% Triton X-100), and afterward loaded with either GTP or GDP (both Sigma-Aldrich) in NL100 buffer (20 mM Hepes/NaOH pH 7.5, 100 mM NaCl, 10 mM MgCl 2 , 0.1% Triton X-100) supplied with 100 μM nucleotide. HeLa cells were transfected 16-18 hours before with the respective FLAG-tagged construct, pelleted, and lysed in NL100 buffer supplemented with 5 mM β-Mercaptoethanol and Complete protease inhibitor (Roche, Mannheim, Germany) for 15 minutes on ice. Cell debris was removed by centrifugation, and the HeLa lysate was incubated for 1-2 hours with the bead-coupled GTPases. After washing three times with lysis buffer, beads were boiled in SDS-PAGE loading buffer and fractions were analyzed by western blotting by loading 5% of input and 50% of pulldown fraction.
Immunoprecipitation
Hela cells were resuspended in modified RIPA buffer (Tris-HCl: 50 mM, pH 7.4, NP-40: 1%, Na-deoxycholate: 0.25%, NaCl: 150 mM, EDTA: 1 mM, Inhibitor Cocktail (Sigma-Aldrich)) and incubated at 4°C for 20 minutes to lyse cells followed by centrifugation. The supernatant was incubated with protein A/G agarose (Thermo Fisher Scientific) for 10 minutes on a roller. Beads were removed by centrifugation. To the precleared lysate, GORAB antibody (Sigma-Aldrich HPA027208, 1:200) was added and incubated overnight at 4°C. The immunocomplex was captured by adding Protein A/G agarose beads and by incubation on a roller for 1 hour. Beads were washed once with modified RIPA buffer and three times with 50 mM ammoniumbicarbonate (pH 8.0), followed by elution with 1% formic acid. Eluated fractions were analyzed by mass spectrometry.
Mass spectrometry analysis
IP samples were reduced by a final concentration of 50 mM DTT and incubated for 1 hour at 56°C. After alkylation, samples were precipitated by ice-cold (−20C°) acetone overnight, dissolved in 50 mM NH 4 HCO 3 , and digested with 0.5 μg of trypsin at 37C°ON. The digests were desalted by C18 stage Tips and dissolved in 5% acetonitrile and 2% formic acid before LC-MS analysis. Nano liquid chromatography, online coupled to a Linear Ion Trap (LTQ)-Orbitrap XL mass spectrometer (Thermo-Electron, Karlsruhe, Germany), was used to sequence peptides eluting from a PicoFrit analytical column (New Objectives, Woburn, MA) with 3-μm C18 resin (Reprosil-AQ Pur, Dr Maisch, Ammerbuch-Entringen, Germany). A nonlinear gradient from 2 to 40% solvent B over 160 minutes at a flow rate of 200 nl min − 1 (solvent A: 97.9% H 2 O, 2% acetonitrile, 0.1% formic acid; solvent B: 97.9% acetonitrile, 2% H 2 O, 0.1% formic acid) was used. A voltage of 1.8 kV was applied for nanoelectrospray generation.
A cycle of one full FT scan mass spectrum (300 − 2,000 m/z, resolution of 60,000 at m/z 400) was followed by 10 datadependent MS/MS scans acquired in the linear ion trap with normalized collision energy (setting at 35%). MaxQuant v1.4.1.2 (Martinsried, Germany) was used for data processing.
